3673-34-5

Basic information

• Product Name: N-(Thiazol-2-yl)carbamic acid ethyl ester
• Synonyms: N-(Thiazol-2-yl)carbamic acid ethyl ester
• CAS NO: 3673-34-5
• Molecular Formula: C₆H₈N₂O₂S
• Molecular Weight: 172.2049
• Mol File: 3673-34-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.344g/cm³
• Refractive Index: 1.592
• CAS DataBase Reference: N-(Thiazol-2-yl)carbamic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-(Thiazol-2-yl)carbamic acid ethyl ester(3673-34-5)
• EPA Substance Registry System: N-(Thiazol-2-yl)carbamic acid ethyl ester(3673-34-5)

Safety Data

• Hazardous Substances Data: 3673-34-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H8N2O2S/c1-2-10-6(9)8-5-7-3-4-11-5/h3-4H,2H2,1H3,(H,7,8,9)

Upstream product

• 96-50-4 2-thiazolylamine 
• 105-39-5 chloroacetic acid ethyl ester 
• 705-87-3 N-(2-thiazolyl)-3-oxo-butanamide 
• 541-41-3 chloroformic acid ethyl ester 
• 16182-04-0 Ethoxycarbonyl isothiocyanate 
• 16357-59-8 N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline 
• 2983-26-8 1,2-dibromoethyl ethyl ether 
• 3673-38-9 N-ethoxycarbonylthiourea 
• 37529-58-1 3-ethoxycarbonylsulfanyl-3-phenyl-N-thiazol-2-yl-acrylamide 
• 37529-42-3 3-phenyl-N-thiazol-2-yl-3-thioxo-propionamide 

Relevant articles and documents

Design, synthesis and biological evaluation of new 2-aminothiazole scaffolds as phosphodiesterase type 5 regulators and COX-1/COX-2 inhibitors

A new series of 2-aminothiazole derivatives was designed and prepared as phosphodiesterase type 5 (PDE5) regulators and COX-1/COX-2 inhibitors. The screening of the synthesized compounds for PDE5 activity was carried out using sildenafil as a reference drug. Strikingly, compounds 23a and 23c were found to have a complete inhibitory effect on PDE5 (100%) at 10 μM without causing hypotension and the limited side effect of PDE5 inhibitors, suggest a distinctive therapeutic role of these derivatives in erectile dysfunction. On the other hand, compounds 5a, 17, 21 and 23b increased the PDE5 activity (PDE5 enhancers) at 10 μM. In addition, the study includes the screening of the COX-1/COX-2 inhibition induced by the synthesized compounds. All tested compounds have an inhibitory effect against COX-1 activity (IC50 = 1.00-6.34 μM range) and COX-2 activity (IC50 = 0.09-0.71 μM range). Moreover, a molecular docking study was implemented to reveal the binding interactions of potent compounds in the binding sites of PDE5 (PDB ID 2H42), COX-1 and COX-2 (PDB ID 3LN1) enzymes. For the interaction with the PDE5 enzyme, activator compounds had a strong binding mode (HB with Gln817:A) than inhibitory derivatives. Both types of compounds are considered as PDE5 regulators. This novel finding will encourage us to discover a new pharmacological application of small chemical entities as the PDE5 enhancer, or will lower side effects as PDE5 inhibitors. All active compounds adopted the Y-shape along the COX-2 active site. This journal is

Non-isocyanate synthesis of N-(1,3-thiazol-2-yl)ureas

-

ANTI-ULCER UREA COMPOUNDS

The invention relates to certain urea derivatives of the formula R 1 CH 2 S(CH 2) 2 NHCONHR 2 where R 1 are certain furanyls, imidazoles and thiazolyls and R 2 are certain imidazoles and thiazolyls. These compounds are H-2 histamine receptor inhibitors and therefore useful in the treatment of ulcers.